This company has been acquired
HARP Stock Overview
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Harpoon Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$23.01 |
| 52 Week High | US$23.21 |
| 52 Week Low | US$3.11 |
| Beta | 2.1 |
| 1 Month Change | 2.49% |
| 3 Month Change | 162.97% |
| 1 Year Change | 243.43% |
| 3 Year Change | -88.71% |
| 5 Year Change | -81.26% |
| Change since IPO | -82.96% |
Recent News & Updates
Recent updates
Improved Revenues Required Before Harpoon Therapeutics, Inc. (NASDAQ:HARP) Stock's 97% Jump Looks Justified
Jan 30
Harpoon Therapeutics, Inc. (NASDAQ:HARP) Looks Inexpensive After Falling 55% But Perhaps Not Attractive Enough
Oct 01Analysts Just Made A Notable Upgrade To Their Harpoon Therapeutics, Inc. (NASDAQ:HARP) Forecasts
Aug 14Forecast: Analysts Think Harpoon Therapeutics, Inc.'s (NASDAQ:HARP) Business Prospects Have Improved Drastically
May 28Harpoon Therapeutics (NASDAQ:HARP) Will Have To Spend Its Cash Wisely
Mar 11Harpoon Therapeutics appoints Luke Walker as CMO
Oct 04Harpoon Therapeutics: A Well Undervalued Tri-Specific Oncology Player
Sep 01Here's Why We're A Bit Worried About Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Situation
Jul 30Harpoon Therapeutics: A T-Cell Engager Platform And A Negative Enterprise Value Makes It A Candidate For My 'Bio Boom' Portfolio
Jul 07Is Harpoon Therapeutics (NASDAQ:HARP) In A Good Position To Invest In Growth?
Mar 08We're Keeping An Eye On Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Rate
Nov 30Harpoon Therapeutics: A First Look
Sep 16Harpoon shares slide after early-stage prostate cancer study data fails to impress
Jun 04Shareholder Returns
| HARP | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.2% | -1.8% | 0.4% |
| 1Y | 243.4% | -2.7% | 21.5% |
Return vs Industry: HARP exceeded the US Biotechs industry which returned 16% over the past year.
Return vs Market: HARP exceeded the US Market which returned 31% over the past year.
Price Volatility
| HARP volatility | |
|---|---|
| HARP Average Weekly Movement | 32.6% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 18.1% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: HARP's share price has been volatile over the past 3 months.
Volatility Over Time: HARP's weekly volatility has increased from 21% to 33% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 53 | Julie Eastland | www.harpoontx.com |
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications.
Harpoon Therapeutics, Inc. Fundamentals Summary
| HARP fundamental statistics | |
|---|---|
| Market cap | US$492.35m |
| Earnings (TTM) | -US$30.50m |
| Revenue (TTM) | US$37.34m |
13.2x
P/S Ratio-16.1x
P/E RatioIs HARP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HARP income statement (TTM) | |
|---|---|
| Revenue | US$37.34m |
| Cost of Revenue | US$58.63m |
| Gross Profit | -US$21.29m |
| Other Expenses | US$9.21m |
| Earnings | -US$30.50m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.43 |
| Gross Margin | -57.02% |
| Net Profit Margin | -81.67% |
| Debt/Equity Ratio | 194.4% |
How did HARP perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/03/11 09:01 |
| End of Day Share Price | 2024/03/11 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Harpoon Therapeutics, Inc. is covered by 12 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Colleen Kusy | Baird |
| Arlinda Lee | Canaccord Genuity |
| Jennifer Kim | Cantor Fitzgerald & Co. |